Terms: = Germ cell tumor AND LMNA, EMD2, 4000, ENSG00000160789, LGMD1B, LDP1, PRO1, LMNC, FPLD, CDDC, HGPS, P02545, LFP, IDC, CMD1A, CDCD1, LMN1, CMT2B1, FPL AND Treatment
87 results:
1. Steroid Efficacy on Audiologic Recovery in Patients With Sudden Sensorineural Hearing Loss and Vestibular Schwannoma: A Retrospective Review.
Huynh PP; Saba ES; Hoerter JE; Jiang N
Otol Neurotol; 2023 Sep; 44(8):780-785. PubMed ID: 37464465
[TBL] [Abstract] [Full Text] [Related]
2. Functionalisation of extracellular vesicles with cyclic-RGDyC potentially for glioblastoma targeted intracellular drug delivery.
Geng T; Leung E; Chamley LW; Wu Z
Biomater Adv; 2023 Jun; 149():213388. PubMed ID: 37003022
[TBL] [Abstract] [Full Text] [Related]
3. Differences in clinical characteristics and prognosis between breast neuroendocrine carcinoma and breast invasive ductal carcinoma: A multicentre population-based study from China.
Wang DY; Li SF; Gao SL; Yuan P; Zhang BL
Cancer Med; 2023 Apr; 12(8):9644-9649. PubMed ID: 36952359
[TBL] [Abstract] [Full Text] [Related]
4. Comparative outcomes of short-term and long-term fractionation with temozolomide in older glioblastoma patients: Single-center experience.
Uysal B; Gamsiz H; Sager O; Dincoglan F; Demiral S; Ozcan F; Colak O; Beyzadeoglu M
J Cancer Res Ther; 2022; 18(6):1610-1615. PubMed ID: 36412419
[TBL] [Abstract] [Full Text] [Related]
5. Metastatic rectal neuroendocrine carcinoma presenting with treatment-refractory immune thrombocytopenia: A case report and literature review.
Bancheno WM; Adidam SR; Melaku MA
Medicine (Baltimore); 2022 Jul; 101(29):e29616. PubMed ID: 35866784
[TBL] [Abstract] [Full Text] [Related]
6. Primary Breast Neuroendocrine tumors: An Analysis of the National Cancer Database.
Martinez EO; Jorns JM; Kong AL; Kijak J; Lee WY; Huang CC; Cortina CS
Ann Surg Oncol; 2022 Oct; 29(10):6339-6346. PubMed ID: 35789311
[TBL] [Abstract] [Full Text] [Related]
7. Phase I study of [
Thivat E; Rouanet J; Auzeloux P; Sas N; Jouberton E; Levesque S; Billoux T; Mansard S; Molnar I; Chanchou M; Fois G; Maigne L; Chezal JM; Miot-Noirault E; D'Incan M; Durando X; Cachin F
BMC Cancer; 2022 Apr; 22(1):417. PubMed ID: 35428211
[TBL] [Abstract] [Full Text] [Related]
8. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors.
Romanski NA; Holmstroem RB; Ellebaek E; Svane IM
Eur J Cancer; 2020 May; 130():211-218. PubMed ID: 32229418
[TBL] [Abstract] [Full Text] [Related]
10. Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project.
De Gregorio A; Nagel G; Möller P; Rempen A; Schlicht E; Fritz S; Flock F; Kühn T; Thiel F; Felberbaum R; Ebner F; De Gregorio N; Friedl TWP; Wiesmüller L; Kuhn P; Schmitt M; Janni W; Rothenbacher D; Huober J
Arch Gynecol Obstet; 2020 Jan; 301(1):273-281. PubMed ID: 31781887
[TBL] [Abstract] [Full Text] [Related]
11. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Nitta RT; Bolin S; Luo E; Solow-Codero DE; Samghabadi P; Purzner T; Aujla PS; Nwagbo G; Cho YJ; Li G
Oncogene; 2019 Oct; 38(42):6867-6879. PubMed ID: 31406250
[TBL] [Abstract] [Full Text] [Related]
12. Breakdown of the blood-eye barrier in choroidal melanoma after proton beam radiotherapy.
Hager A; Meissner F; Riechardt AI; Bonaventura T; Löwen J; Heufelder J; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2323-2328. PubMed ID: 31300898
[TBL] [Abstract] [Full Text] [Related]
13. A radiomics nomogram based on multiparametric MRI might stratify glioblastoma patients according to survival.
Zhang X; Lu H; Tian Q; Feng N; Yin L; Xu X; Du P; Liu Y
Eur Radiol; 2019 Oct; 29(10):5528-5538. PubMed ID: 30847586
[TBL] [Abstract] [Full Text] [Related]
14. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
[TBL] [Abstract] [Full Text] [Related]
15. Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia.
Li L; Wan X; Feng F; Ren T; Yang J; Zhao J; Jiang F; Xiang Y
BMC Cancer; 2018 May; 18(1):585. PubMed ID: 29792175
[TBL] [Abstract] [Full Text] [Related]
16. The Clinical Features and Surgical Outcomes of Spinal Cord Tanycytic Ependymomas: A Report of 40 Cases.
Tao X; Hou Z; Hao S; Zhang Q; Wu Z; Zhang J; Liu B
World Neurosurg; 2017 Oct; 106():60-73. PubMed ID: 28647654
[TBL] [Abstract] [Full Text] [Related]
17. [Protective effect of BAG-1L mediated by lentivirus in human neuroblastoma cells induced by hypoxia].
Wang Y; Li Q; Jia C; Xie C; Song Y; Zhang N; Qu Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Mar; 29(3):239-243. PubMed ID: 28627344
[TBL] [Abstract] [Full Text] [Related]
18. ZEB1 regulates glioma stemness through LIF repression.
Edwards LA; Li A; Berel D; Madany M; Kim NH; Liu M; Hymowitz M; Uy B; Jung R; Xu M; Black KL; Rentsendorj A; Fan X; Zhang W; Yu JS
Sci Rep; 2017 Feb; 7(1):69. PubMed ID: 28246407
[TBL] [Abstract] [Full Text] [Related]
19. Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base.
Mateo AM; Pezzi TA; Sundermeyer M; Kelley CA; Klimberg VS; Pezzi CM
J Surg Oncol; 2016 Oct; 114(5):533-536. PubMed ID: 27393599
[TBL] [Abstract] [Full Text] [Related]
20. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
[TBL] [Abstract] [Full Text] [Related]
[Next]
